Evidence map›Paper›PMID 33282627›Full record

ArticleJournal of benefit-cost analysis2019

Conducting Benefit-Cost Analysis in Low- and Middle-Income Countries: Introduction to the Special Issue.

Lisa A Robinson, James K Hammitt, Dean T Jamison, Damian G Walker

Abstract read
In one paragraph

Article in Journal of benefit-cost analysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Lisa Robinson: Benefit-Cost Analyses for Evidence-Based Decisions.Risk analysis : an official publication of the Society for Risk Analysis · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  20. Mortality Benefits and Control Costs of Improving Air Quality in Mexico City: The Case of Heavy Duty Diesel Vehicles.Risk analysis : an official publication of the Society for Risk Analysis · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lisa A RobinsonLisa A. Robinson, Harvard T.H. Chan School of Public Health (Center for Risk Analysis & Center for Health Decision Science), 718 Huntington Avenue, Boston, MA 02115, USA.
James K HammittJames K. Hammitt: Harvard T.H. Chan School of Public Health (Center for Risk Analysis & Center for Health Decision Science), 718 Huntington Avenue, Boston, MA 02115, USA and Toulouse School of Economics, Université de Toulouse Capitole, 21 allée de Brienne, 31000 Toulouse, France.
Dean T JamisonDean T. Jamison: University of California, San Francisco (Global Health Sciences), 550 16th Street, San Francisco, CA 94143, USA.
Damian G WalkerDamian G. Walker: Bill & Melinda Gates Foundation, 500 Fifth Avenue North, Seattle, WA 98109, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Investing in global health and development requires making difficult choices about what policies to pursue and what level of resources to devote to different initiatives. Methods of economic evaluation are well established and widely used to quantify and compare the impacts of alternative investments. However, if not well conducted and clearly reported, these evaluations can lead to erroneous conclusions. Differences in analytic methods and assumptions can obscure important differences in impacts. To increase the comparability of these evaluations, improve their quality, and expand their use, this special issue includes a series of papers developed to support reference case guidance for benefit-cost analysis. In this introductory article, we discuss the background and context for this work, summarize the process we are following, describe the overall framework, and introduce the articles that follow.

Indexed as

benefit-cost analysisD6H4I1low- and middle-income countriesQ5value per statistical life

Identifiers

PMID33282627
PMCPMC7672367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.